AU703203B2 - Inhibitors of farnesyl-protein transferase - Google Patents

Inhibitors of farnesyl-protein transferase

Info

Publication number
AU703203B2
AU703203B2 AU18444/97A AU1844497A AU703203B2 AU 703203 B2 AU703203 B2 AU 703203B2 AU 18444/97 A AU18444/97 A AU 18444/97A AU 1844497 A AU1844497 A AU 1844497A AU 703203 B2 AU703203 B2 AU 703203B2
Authority
AU
Australia
Prior art keywords
farnesyl
inhibitors
protein transferase
transferase
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU18444/97A
Other languages
English (en)
Other versions
AU1844497A (en
Inventor
Christopher J. Dinsmore
George D. Hartman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9605708.8A external-priority patent/GB9605708D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU1844497A publication Critical patent/AU1844497A/en
Application granted granted Critical
Publication of AU703203B2 publication Critical patent/AU703203B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU18444/97A 1996-01-30 1997-01-27 Inhibitors of farnesyl-protein transferase Ceased AU703203B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1079896P 1996-01-30 1996-01-30
US60/010798 1996-01-30
GB9605708 1996-03-19
GBGB9605708.8A GB9605708D0 (en) 1996-03-19 1996-03-19 Inhibitors of farnesyl-protein transferase
PCT/US1997/001354 WO1997027852A1 (en) 1996-01-30 1997-01-27 Inhibitors of farnesyl-protein transferase

Publications (2)

Publication Number Publication Date
AU1844497A AU1844497A (en) 1997-08-22
AU703203B2 true AU703203B2 (en) 1999-03-18

Family

ID=26308955

Family Applications (1)

Application Number Title Priority Date Filing Date
AU18444/97A Ceased AU703203B2 (en) 1996-01-30 1997-01-27 Inhibitors of farnesyl-protein transferase

Country Status (5)

Country Link
US (1) US6066738A (cg-RX-API-DMAC10.html)
EP (1) EP0944387A1 (cg-RX-API-DMAC10.html)
JP (1) JP2000504014A (cg-RX-API-DMAC10.html)
AU (1) AU703203B2 (cg-RX-API-DMAC10.html)
WO (1) WO1997027852A1 (cg-RX-API-DMAC10.html)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0880320A4 (en) * 1996-01-30 1999-06-16 Merck & Co Inc FARNESYL-PROTEIN TRANSFERASE INHIBITORS
US5972966A (en) * 1996-12-05 1999-10-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1999027928A1 (en) * 1997-12-04 1999-06-10 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2336054A1 (en) 1998-07-02 2000-01-13 Merck And Co., Inc. Inhibitors of prenyl-protein transferase
EP1090011A4 (en) 1998-07-02 2005-04-06 Merck & Co Inc INHIBITORS OF PRENYL-PROTEIN TRANSFERASE
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
NZ525513A (en) 1998-08-07 2004-09-24 Pont Pharmaceuticals Du Succinoylamino lactams as inhibitors of Abeta protein production
AU778005B2 (en) 1998-12-24 2004-11-11 Bristol-Myers Squibb Pharma Company Succinoylamino benzodiazepines as inhibitors of Abeta protein production
US6960576B2 (en) 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
CA2387493A1 (en) 1999-10-08 2001-04-19 Lorin Andrew Thompson Amino lactam sulfonamides as inhibitors of a.beta. protein production
AU2001239791A1 (en) 2000-02-17 2001-08-27 Du Pont Pharmaceuticals Company Succinoylamino carbocycles and heterocycles as inhibitors of abeta protein production
US6495540B2 (en) 2000-03-28 2002-12-17 Bristol - Myers Squibb Pharma Company Lactams as inhibitors of A-β protein production
IL151576A0 (en) 2000-04-03 2003-04-10 Bristol Myers Squibb Pharma Co Cyclic lactams as inhibitors of a-beta protein production
MXPA02009729A (es) 2000-04-03 2003-03-27 Bristol Myers Squibb Pharma Co Lactamas ciclicas como inhibidores de la produccion de la proteina a-beta.
AU2001251444A1 (en) 2000-04-10 2001-10-23 Merck And Co., Inc. Inhibitors of prenyl-protein transferase
WO2001077086A1 (en) 2000-04-11 2001-10-18 Dupont Pharmaceuticals Company SUBSTITUTED LACTAMS AS INHIBITORS OF Aβ PROTEIN PRODUCTION
EP1268450A1 (en) 2000-06-01 2003-01-02 Bristol-Myers Squibb Pharma Company Lactams substituted by cyclic succinates as inhibitors of a-beta protein production
JP4181408B2 (ja) 2001-01-30 2008-11-12 メルク エンド カムパニー インコーポレーテッド 肥満、糖尿病及び脂質異常を治療するためのアシルスルファミド類
US6624162B2 (en) 2001-10-22 2003-09-23 Pfizer Inc. Imidazopyridine compounds as 5-HT4 receptor modulators
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
CA2472746A1 (en) 2002-01-14 2003-07-24 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof
PL373043A1 (en) 2002-03-26 2005-08-08 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
CA2477764A1 (en) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
DE60322713D1 (de) 2002-08-21 2008-09-18 Boehringer Ingelheim Pharma Substituierte dihydrochinoline als glucocorticoid-mmimetika,verfahren zu deren herstellung, pharmazeutische zubereitungen und deren verwendung
EA011095B1 (ru) 2002-08-29 2008-12-30 Бёрингер Ингельхайм Фармасьютиклз, Инк. Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний
BR0314584A (pt) 2002-09-20 2005-08-09 Pfizer Compostos piperidinil-imidazopiridina n-substituìda como moduladores e receptores 5-ht4
DOP2003000703A (es) 2002-09-20 2004-03-31 Pfizer Compuestos de imidazopiradina como agonistas del receptor 5-ht4
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
AU2003297471A1 (en) 2003-01-03 2004-08-10 Boehringer Ingelheim Pharmaceuticals, Inc. 1-propanol and 1-propylamine derivatives and their use as glucocorticoid ligands
KR101224235B1 (ko) 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
EP2256106B1 (en) 2003-07-22 2015-05-06 Astex Therapeutics Limited 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
CA2536238C (en) 2003-08-18 2015-04-07 Medimmune, Inc. Humanization of antibodies
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
UY28526A1 (es) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
EP1669348A4 (en) 2003-09-30 2009-03-11 Eisai R&D Man Co Ltd NEW ANTIPILIC AGENT CONTAINING A HETEROCYCLIC COMPOUND
DE602004007539T2 (de) 2003-10-16 2007-10-25 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Stereoselektive synthese bestimmter trifluormethylsubstituierter alkohole
US7795272B2 (en) 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
AU2005254800B2 (en) 2004-06-15 2010-12-09 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
EP1809326A4 (en) 2004-10-27 2009-11-04 Medimmune Inc MODULATION OF ANTIBODY SPECIFICITY BY MEASURING ADAPTATION OF ITS AFFINITY TO AN APPARENT ANTIGEN
WO2006071609A2 (en) 2004-12-27 2006-07-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
KR101155335B1 (ko) * 2005-01-07 2012-06-11 엘지전자 주식회사 이동통신 단말기의 멀티미디어 메시지 동작방법
AR052660A1 (es) * 2005-01-21 2007-03-28 Astex Therapeutics Ltd Derivados de pirazol para inhibir la cdk's y gsk's
RU2007131101A (ru) * 2005-01-21 2009-02-27 Астекс Терапьютикс Лимитед (Gb) Комбинации пиразольных ингибиторов киназы и других средств против злокачественных новообразований
CN101146532B (zh) * 2005-01-21 2012-05-09 阿斯泰克斯治疗有限公司 药物化合物
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
ES2552338T3 (es) * 2005-01-21 2015-11-27 Astex Therapeutics Limited Compuestos farmacéuticos
US20080139620A1 (en) * 2005-01-21 2008-06-12 Astex Therapeutics Limited Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's
AR054425A1 (es) * 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
WO2006093271A1 (ja) * 2005-03-03 2006-09-08 Mitsubishi Rayon Co., Ltd. ポリマー粒子、これを含む樹脂組成物、成形体
WO2006102095A2 (en) 2005-03-18 2006-09-28 Medimmune, Inc. Framework-shuffling of antibodies
US7829585B2 (en) 2005-03-30 2010-11-09 Eisai R&D Management Co., Ltd. Antifungal agent containing pyridine derivative
JP2008546805A (ja) 2005-06-23 2008-12-25 メディミューン，エルエルシー 最適な凝集および断片化プロフィールを有する抗体製剤
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
JP2009536187A (ja) * 2006-05-05 2009-10-08 アステックス・セラピューティクス・リミテッド 癌の処置のための４−（２，６−ジクロロ−ベンゾイルアミノ）−１ｈ−ピラゾール−３−カルボン酸（１−メタンスルホニル−ピペリジン−４−イル）−アミド
JP2009536186A (ja) * 2006-05-08 2009-10-08 アステックス・セラピューティクス・リミテッド 癌処置のためのジアゾール誘導体の医薬組合せ
JP2009543771A (ja) * 2006-07-14 2009-12-10 アステックス・セラピューティクス・リミテッド 医薬化合物
MX2009002151A (es) 2006-08-28 2009-07-03 Kirin Pharma Kk Anticuerpos monoclonales humanos especificos para light humano antagonistas.
CN101547909A (zh) 2006-12-06 2009-09-30 贝林格尔.英格海姆国际有限公司 糖皮质激素模拟物、其制备方法、药物组合物及其用途
EP2068923A4 (en) 2007-03-30 2010-11-24 Medimmune Llc ANTIBODIES HAVING REDUCED DEAMIDATION PROFILES
KR101686247B1 (ko) 2007-10-31 2016-12-14 메디뮨 엘엘씨 단백질 스캐폴드
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
BRPI0915680A2 (pt) 2008-06-06 2019-09-24 Boehringer Ingelheim Int miméticos de glicocorticoide, métodos de prepará-los, composições farmacêuticas, e usos dos mesmos
DK2668210T3 (da) 2011-01-26 2020-08-24 Celldex Therapeutics Inc Anti-kit antistoffer og anvendelser deraf
WO2014018625A1 (en) 2012-07-25 2014-01-30 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
JP2015533832A (ja) 2012-10-09 2015-11-26 アイジェニカ バイオセラピューティクス インコーポレイテッド 抗Ｃ１６ｏｒｆ５４抗体およびその使用方法
NZ714765A (en) 2013-06-06 2021-12-24 Pf Medicament Anti-c10orf54 antibodies and uses thereof
CA3090644C (en) 2013-08-26 2023-02-07 Biontech Research And Development, Inc. Nucleic acids encoding human antibodies to sialyl-lewisa
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR102614642B1 (ko) 2014-06-04 2023-12-19 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 강글리오사이드 ｇｄ２에 대한 사람 단클론 항체
GB201415569D0 (en) 2014-09-03 2014-10-15 C4X Discovery Ltd Therapeutic Compounds
BR112017012344B1 (pt) 2014-12-11 2024-02-06 Pierre Fabre Medicament Anticorpo anti-c10orf54 ou fragmento de ligação ao antígeno do mesmo, conjugado anticorpo-fármaco, composição farmacêutica, kit, seus usos, polinucleotídeo, vetor de expressão e métodos de produção do anticorpo ou fragmento de ligação ao antígeno e de detecção c10orf54 em uma amostra
PT3265123T (pt) 2015-03-03 2023-02-01 Kymab Ltd Anticorpos, usos e métodos
CN108925136B (zh) 2015-12-02 2022-02-01 斯特赛恩斯公司 特异于糖基化的btla（b和t淋巴细胞衰减因子）的抗体
KR20250065433A (ko) 2015-12-02 2025-05-12 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체와 분자 및 그의 치료 용도
TN2018000188A1 (en) 2015-12-15 2019-10-04 Astrazeneca Ab Isoindole compounds
GB201601703D0 (en) 2016-01-29 2016-03-16 C4X Discovery Ltd Therapeutic compounds
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018222685A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
JP7369038B2 (ja) 2017-05-31 2023-10-25 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子並びにその治療的使用
WO2018226671A1 (en) 2017-06-06 2018-12-13 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
EP3638661A1 (en) 2017-06-14 2020-04-22 Astrazeneca AB 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators
JP7256796B2 (ja) 2017-10-13 2023-04-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔｈｏｍｓｅｎ－ｎｏｕｖｅｌｌｅ（ｔｎ）抗原に対するヒト抗体
CA3106418A1 (en) 2018-07-20 2020-01-23 Pierre Fabre Medicament Receptor for vista
UA130303C2 (uk) 2019-12-06 2026-01-14 Вертекс Фармасьютикалз Інкорпорейтед Заміщені тетрагідрофурани як модулятори натрієвих каналів
MX2023014378A (es) 2021-06-04 2023-12-15 Vertex Pharma N-(hidroxialquil(hetero)aril)tetrahidrofurano carboxamidas como moduladores de canales de sodio.

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1204720A (en) * 1982-09-30 1986-05-20 Hajimu Kitahara Packing materials for chromatographic use and a method for analysis of an enantiomer mixture using the same
US4749713A (en) * 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
CA1326852C (en) * 1987-10-16 1994-02-08 Yukihisa Goto Condensed heterocyclic compounds, a process for preparing the same and a herbicidal composition thereof
EP0387431A1 (en) * 1989-03-14 1990-09-19 Beecham Group Plc Imidazole derivatives, process for their preparation and their pharmaceutical use
US5234917A (en) * 1989-12-29 1993-08-10 Finkelstein Joseph A Substituted 5-(alkyl)carboxamide imidazoles
US5141851A (en) * 1990-04-18 1992-08-25 Board Of Regents, The University Of Texas System Isolated farnesyl protein transferase enzyme
US5340828A (en) * 1991-09-30 1994-08-23 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US5238922A (en) * 1991-09-30 1993-08-24 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US5352705A (en) * 1992-06-26 1994-10-04 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US5504212A (en) * 1992-10-29 1996-04-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5326773A (en) * 1992-10-29 1994-07-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5468733A (en) * 1993-09-30 1995-11-21 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5439918A (en) * 1994-03-14 1995-08-08 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5571792A (en) * 1994-06-30 1996-11-05 Warner-Lambert Company Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
US5585359A (en) * 1994-09-29 1996-12-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5571835A (en) * 1994-09-29 1996-11-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5491164A (en) * 1994-09-29 1996-02-13 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5534537A (en) * 1995-03-29 1996-07-09 Merck & Co., Inc. Prodrugs of inhibitors of farnesyl-protein transferase
US5578629A (en) * 1995-03-29 1996-11-26 Merck & Co., Inc. Benzamide-containing inhibitors of farnesyl-protein transferase
JPH11503419A (ja) * 1995-03-29 1999-03-26 メルク エンド カンパニー インコーポレーテッド ファルネシル−タンパク質トランスフェラーゼ阻害剤
PL330120A1 (en) * 1996-05-22 1999-04-26 Warner Lambert Co Farnesilic protein transferase inhibitors

Also Published As

Publication number Publication date
JP2000504014A (ja) 2000-04-04
EP0944387A1 (en) 1999-09-29
WO1997027852A1 (en) 1997-08-07
US6066738A (en) 2000-05-23
EP0944387A4 (cg-RX-API-DMAC10.html) 1999-09-29
AU1844497A (en) 1997-08-22

Similar Documents

Publication Publication Date Title
AU703203B2 (en) Inhibitors of farnesyl-protein transferase
AU2734797A (en) Inhibitors of farnesyl-protein transferase
AU2670297A (en) Inhibitors of farnesyl-protein transferase
AU2593097A (en) Inhibitors of farnesyl-protein transferase
AU2253097A (en) Inhibitors of farnesyl-protein transferase
AU2430197A (en) Inhibitors of farnesyl-protein transferase
AU1988495A (en) Inhibitors of farnesyl-protein transferase
AU2555997A (en) Inhibitors of farnesyl-protein transferase
AU3373195A (en) Inhibitors of farnesyl-protein transferase
GB9604311D0 (en) Inhibitors of farnesyl-protein transferase
AU2598897A (en) Inhibitors of farnesyl-protein transferase
AU2605897A (en) Inhibitors of farnesyl-protein transferase
AU2552497A (en) Inhibitors of farnesyl-protein transferase
AU2605797A (en) Inhibitors of farnesyl-protein transferase
AU2587597A (en) Inhibitors of farnesyl-protein transferase
AU1851697A (en) Inhibitors of farnesyl-protein transferase
AU2432697A (en) Inhibitors of farnesyl-protein transferase
AU2432597A (en) Inhibitors of farnesyl-protein transferase
AU2430397A (en) Inhibitors of farnesyl-protein transferase
AU2554897A (en) Inhibitors of farnesyl-protein transferase
AU2600597A (en) Inhibitors of farnesyl-protein transferase
AU2602097A (en) Inhibitors of farnesyl-protein transferase
AU2593297A (en) Inhibitors of farnesyl-protein transferase
AU1952697A (en) Inhibitors of farnesyl-protein transferase
AU2587997A (en) Inhibitors of farnesyl-protein transferase

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired